At YAKADA HEALTH Inc., innovation is more than a goal—it’s our responsibility. Our lead investigational product, YKD-001, marks a pivotal step in fulfilling our mission to bridge traditional African medicine with modern science. We are proud to announce that YKD-001 is advancing steadily toward Phase I clinical trials, guided by a robust clinical development plan and the support of an esteemed International Scientific Advisory Board.

YKD-001 is a plant-derived therapeutic formulated through rigorous ethnopharmacological research, advanced extraction technologies, and preclinical pharmacology testing. Rooted in traditional African healing practices, this compound has shown significant potential in modulating inflammatory pathways and promoting immune system balance. Its promising safety profile and efficacy indicators in preclinical models have attracted the attention of researchers across multiple disciplines.

With Phase I clinical trials on the horizon, we are entering a critical phase of validation. This trial will focus on evaluating the safety, tolerability, and pharmacokinetics of YKD-001 in healthy volunteers. Our clinical design adheres to international GCP (Good Clinical Practice) standards, ensuring integrity, transparency, and scientific rigor.

Key collaborators, including institutions in Africa, Europe, and North America, are playing an instrumental role in refining the trial protocol. Their insights help us maintain a culturally-informed yet globally-aligned research pathway. The International Advisory Board, comprising clinicians, pharmacologists, and regulatory experts, will provide continuous guidance throughout the clinical phases.

We believe YKD-001 represents a model for future development of traditional plant-based therapeutics—one that combines ancestral knowledge with world-class biomedical science. Stay tuned for trial enrollment dates, site announcements, and early data insights as we continue this groundbreaking journey.